Adequacy of Peripheral Blood Stem Cell Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine: A Pilot Project and a Proof of Concept Study
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the efficacy of G-CSF induced PBSC mobilization after two cycles of rituximab and Bendamustine (BR) as salvage therapy in patients with relapsed non-Hodgkins lymphoma
Quarterly
Yes
Siddhartha Ganguly, MD
Principal Investigator
University of Kansas
United States: Food and Drug Administration
11908
NCT01022021
January 2010
December 2013
Name | Location |
---|---|
University of Kansas Medical Center | Kansas City, Kansas 66160-7353 |